$ATHE News

Last published 1w ago

1w agoATHEAlterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate UpdateGlobeNewswireHighlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA)New U.S. composition of matter patent granted for ATH434, extending
1mo agoATHEAlterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing
2mo agoATHEAlterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026GlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing
3mo agoATHEAlterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434GlobeNewswire– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential – – Strengthens ATH434’s intellectual property portfolio as it
3mo agoATHEAlterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth ConferenceGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing
3mo agoATHEAlterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate UpdateGlobeNewswireHighlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support
3mo agoATHEAlterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026GlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing
4mo agoATHEAlterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System AtrophyGlobeNewswire– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory
5mo agoATHEAlterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System AtrophyGlobeNewswire– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary
5mo agoATHEAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System AtrophyGlobeNewswire– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 –
6mo agoATHEAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System AtrophyGlobeNewswire– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple
6mo agoATHEAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026GlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
6mo agoATHEAlterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate UpdateGlobeNewswireHighlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA
6mo agoATHEAlterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System AtrophyGlobeNewswire– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing
6mo agoATHEAlterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of NeurologyGlobeNewswire- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported
6mo agoATHEAlterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of DirectorsGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
6mo agoATHEAlterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual MeetingGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
7mo agoATHEAlterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System AtrophyGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
7mo agoATHEAlterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 ProgramGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
8mo agoATHEAlterity Therapeutics to Participate in the Bell Potter Healthcare Horizons SummitGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
8mo agoATHEAlterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical AdvisorGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
8mo agoATHEAlterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying TreatmentsGlobeNewswire– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN FRANCISCO, March
9mo agoATHEAlterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate UpdateGlobeNewswire− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple
9mo agoATHEAlterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026GlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
12mo agoATHEAlterity Therapeutics to Present at the Bell Potter Healthcare Virtual ConferenceGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous SystemGlobeNewswire– Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia and SAN
1y agoATHEAlterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow ReportGlobeNewswireHighlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in
1y agoATHEAlterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement DisordersGlobeNewswire– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker
1y agoATHEAlterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement DisordersGlobeNewswire– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics
1y agoATHEAlterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual MeetingGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Raises A$20.0 million in Strategic PlacementGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics to Present at the Biotech ShowcaseGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAppendix 4C – Q4 FY25 Quarterly Cash Flow ReportGlobeNewswireHighlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented additional analyses
1y agoATHEAlterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System AtrophyGlobeNewswire– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434
1y agoATHEAlterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History StudyGlobeNewswire– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE,
1y agoATHEAlterity Therapeutics to Provide Corporate Update in Fireside ChatGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Prominently Featured at the International MSA CongressGlobeNewswire– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein
1y agoATHEAlterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA CongressGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System AtrophyGlobeNewswire– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH,
1y agoATHEAppendix 4C – Q3 FY25 Quarterly Cash Flow ReportGlobeNewswireHighlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacyPhase 2 data featured in an oral presentation
1y agoATHEAlterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA SymposiumGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual MeetingGlobeNewswire– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025
1y agoATHEAlterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual MeetingGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System AtrophyGlobeNewswire– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity
1y agoATHEAlterity Therapeutics Raises A$40.0 million in PlacementGlobeNewswire– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Australia and SAN
1y agoATHEAlterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical EfficacyGlobeNewswire– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron
1y agoATHEAppendix 4C – Q2 FY25 Quarterly Cash Flow ReportGlobeNewswireHighlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November 2024Positive interim
1y agoATHEAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
1y agoATHEAlterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System AtrophyGlobeNewswire– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE
1y agoATHEAlterity Therapeutics Appoints Abby Macnish Niven as Company SecretaryGlobeNewswireMELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Niven as Alterity's